Advancing Bacteriophage for the Treatment of Bacterial Infections

AmpliPhi BioSciences Corporation is advancing the fight against antibiotic resistance through the development of innovative antibacterial solutions. We invite you to learn more about our proprietary bacteriophage technology and the promise it holds for combating critical health issues facing society.

Antibiotic resistance is one of the most pressing health issues facing the world today. Increasing antibiotic resistance levels are creating an environment in which even commonplace infections could again cause high mortality rates as was the case before the advent of widespread antibiotic usage.

Harnessing Viruses in theWar Against Disease

AmpliPhi seeks to employ the power of highly specific bacteriophages to fight infection. The Company’s proprietary approach utilizes bacteriophages, naturally occurring viruses that target and destroy infecting bacteria.

Lead Therapeutic Programs Targeting Major Unmet Medical Needs in Infectious Disease

Our lead programs include AmpliPhage-001 for the treatment of P. aeruginosa lung infections in CF patients and AmpliPhage-002 for the treatment of methicillin-resistant S. aureus (MRSA) infections.

Advancing Bacteriophage for the Treatment of Bacterial Infections

AmpliPhi BioSciences Corporation is advancing the fight against antibiotic resistance through the development of innovative antibacterial solutions. We invite you to learn more about our proprietary bacteriophage technology and the promise it holds for combating critical health issues facing society.

AmpliPhi -the global leader in developing phage therapy for treating infectious disease.

AmpliPhi Biosciences is a biotechnology company focused on the discovery, development and commercialization of novel phage therapeutics. Our proprietary pipeline is based on the use of bacteriophages, a family of viruses that infect only bacteria.

Latest News

September 2nd 2015

AmpliPhi Biosciences Announces Appointment of Alexander Gaidamaka as Vice President of Chemisty, Manufacturing and Control

More

August 18th 2015

AmpliPhi Biosciences Announces Approval of Common Stock Listing on NYSE MKT

More

Events and Presentations

Sept. 8-10, 2015, Rodman & Renshaw 17th Annual Global Investment Conference

Investors

View our Investors Relations area.

More

 

Subscribe